Gene · 338413
NIH grants2,325
NIH grants whose papers are about the gene, through NIH's grant-paper links.
101 to 120 of 2,325
Download this page as JSON| Grant | Title | TAS2R63P papers | Newest fiscal year |
|---|---|---|---|
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 2 | 2025 |
| P30DK072476 | Pennington/Louisiana NORC | 2 | 2025 |
| P50CA097190 | Head and Neck Cancer SPORE | 2 | 2025 |
| P50CA101942 | DF/HCC Kidney Cancer SPORE (supplement) | 2 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 2 | 2025 |
| P50CA186784 | Translational Research in Breast Cancer | 2 | 2025 |
| P50CA196516 | University of Texas Southwestern Medical Center SPORE in Kidney Cancer | 2 | 2025 |
| R01AI051321 | Structure-based engineering of immune cytokine signaling | 2 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 2 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 2 | 2025 |
| R01CA187318 | Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependence | 2 | 2025 |
| R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 2 | 2025 |
| R01CA230745 | Dissecting KRAS oncoprotein signaling with small molecule inhibitors | 2 | 2025 |
| R01CA251858 | Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | 2 | 2025 |
| R01DK105129 | MECHANISMS OF CHIEF CELL DEDIFFERENTIATION | 2 | 2025 |
| R01HL118979 | Enhancing Treg Therapeutic Efficacy in GVHD | 2 | 2025 |
| R01HL141408 | JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target | 2 | 2025 |
| R35CA197570 | Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation | 2 | 2025 |
| R35CA197695 | Translating genomic discoveries to improved outcomes for high risk acute leukemia | 2 | 2025 |
| R35CA210057 | Integrating targeted therapy and immunotherapy to break through cancer | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/grants?page=6